Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 27 August 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Suboptimal therapy among ulcerative colitis and Crohn's disease patients

The latest issue of the Alimentary Pharmacology & Therapeutics performs a real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.

News image

Treatments for Crohn's disease and ulcerative colitis are not uniformly effective, thus necessitating dose changes, switching, and augmentation and carry adverse event risk, often requiring discontinuation, which reduces treatment benefits.

Dr Rubin and colleagues from Illinois, USA assessed continuity of and changes to initial Crohn's disease and ulcerative colitis treatments, as well as costs associated with specific parameters defining suboptimal therapy.

Commercial US insurance claims were retrospectively analyzed.

Crohn's disease and ulcerative colitis patients receiving monotherapy with 5-aminosalicylates (5-ASAs), corticosteroids, immunomodulators (IM) or biologics were included.

Continuity of and changes to initial therapy and associated costs were assessed over 12 months following therapy initiation.

80% of patients had 1 or more suboptimal therapy markers
Alimentary Pharmacology & Therapeutics

Suboptimal therapy included discontinuation or switch, dose escalation, augmentation, inadequate loading, prolonged corticosteroids use, surgery or hospitalization.

The researchers included 13,005 Crohn's disease, and 19,878 ulcerative colitis patients.

Augmentation was a common index therapy change in both Crohn's disease and ulcerative colitis patients.

The research team found that approximately 50% of Crohn's disease, and ulcerative colitis 5-ASA initiators discontinued/interrupted treatment.

The team noted that approximately 80% of Crohn's disease, and ulcerative colitis patients had 1 or more suboptimal therapy markers.

The research team observed that mean all-cause total costs per Crohn's disease patient were significantly higher in those with vs without suboptimal therapy.

The team noted that in ulcerative colitis, the disparity was smaller.

Dr Rubin's team concludes, "Frequent dose and treatment changes were observed in all classes of initial ulcerative colitis and Crohn's disease treatments."

"The economic impact of suboptimal therapy among ulcerative colitis and Crohn's disease patients is substantial."

Aliment Pharmacol Ther 2014: 39(10): 11431155
07 May 2014

Go to top of page Email this page Email this page to a colleague

 26 August 2016 
Bleeding after endoscopic dissection-induced gastric ulcers
 26 August 2016 
Reasons for premature surveillance colonoscopy
 26 August 2016 
Celiac disease therapeutics
 25 August 2016 
Post-infectious IBS in C. diff
 25 August 2016 
Stool DNA test for colorectal cancer screening
 25 August 2016 
Short-chain fatty acids in mixed refractory constipation
 24 August 2016 
Genetics and therapy response in IBD
 24 August 2016 
Hep B after infant vaccination program
 24 August 2016 
Obeticholic acid for primary biliary cholangitis
 23 August 2016 
Colorectal cancer genetics as biomarkers
 23 August 2016 
Prognostic test for mortality after liver transplant
 23 August 2016 
Postoperative mortality in elderly with IBD
 22 August 2016 
Celiac disease in the elderly
 22 August 2016 
Laparoscopic vs open colectomy databases
 22 August 2016 
Mucosal healing and ulcerative colitis outcomes
 19 August 2016 
Dietary questionnaire for GI clinics
 19 August 2016 
Botox treatment for chronic anal fissure
 19 August 2016 
Myeloid-derived suppressor cells in GI cancers
 18 August 2016 
Gallstone formation determinants
 18 August 2016 
Age disparities in IBD therapy
 18 August 2016 
Seasonal variation in diverticulitis
 17 August 2016 
IBD activity score for routine clinical use
 17 August 2016 
Attitudes to H. pylori in primary care
 17 August 2016 
Nonselective β-blockers and mortality in cirrhosis
 16 August 2016 
Upper GI lesions in adults with IBD
 16 August 2016 
C. difficile infection and mortality when managed by GI surgeons
 16 August 2016 
HCV eradication in cirrhosis
 15 August 2016 
Predicting favorable outcomes in IBD
 15 August 2016 
Scoring system predicted microscopic colitis
 15 August 2016 
Mortality in spontaneous bacterial peritonitis
 12 August 2016 
Recurrence of resected gastric cancer
 12 August 2016 
Screening for pancreatic cancer
 12 August 2016 
Index for diagnostic accuracy of Crohn's
 11 August 2016 
Colorectal neoplasm on surveillance colonoscopies
 11 August 2016 
Bowel disease in primary care patients with bowel symptoms
 11 August 2016 
Diagnosis in covert hepatic encephalopathy
 10 August 2016 
Maintenance therapy for children with eosinophilic esophagitis
 10 August 2016 
Moderate alcohol use and insulin action in HCV
 10 August 2016 
Consensus on the management of GERD
 09 August 2016 
Pancreatitis quality of life instrument
 09 August 2016 
Gallstone disease and NAFLD
 09 August 2016 
Steroid dependency and IBD
 08 August 2016 
Venous thromboembolism in celiac disease
 08 August 2016 
C. diff in IBD 
 08 August 2016 
Gut-directed hypnotherapy vs low FODMAP diet in IBS
 05 August 2016 
Therapy for H.pylori treatment
 05 August 2016 
Obesity and the development of NAFLD
 05 August 2016 
Obesity and CVD in celiac disease
 04 August 2016 
Bleeding after endoscopic resection of colorectal lesions
 04 August 2016 
Novel risk factor for post-ERCP pancreatitis
 04 August 2016 
Ondansetron for children with acute gastroenteritis
 03 August 2016 
Post-colonoscopy complications
 03 August 2016 
IVF in women with IBD
 03 August 2016 
Post-operative pancreatic fistulae after pancreatic surgery
 02 August 2016 
H. pylori in children
 02 August 2016 
Gastric cancer in patients with gastric intestinal metaplasia
 02 August 2016 
Behavioral changes and bariatric surgery
 01 August 2016 
Relapse after cessation of oral antiviral treatment in Hep B
 01 August 2016 
Antimicrobial resistance of H. pylori
 01 August 2016 
Colorectal cancers in IBD

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us